OTLC - Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets | Benzinga

The global retinoblastoma treatment market size was estimated to be $2.62 billion in 2023 and is expected to reach $4.20 billion by 2034 with a CAGR of 4.38% over 2024-2034. Rising incidence of retinoblastoma, early diagnosis and treatment, increasing healthcare expenditure, growing awareness of retinoblastoma treatment options, development of new treatments and government initiatives will drive the market's growth.  

Recently, the FDA granted accelerated approval to Iovance Biotherapeutics' (NASDAQ:IOVA) lifileucel (Amtagvi) to treat inoperable or metastatic melanoma, making it the first and only one-time tumor-infiltrating lymphocyte (TIL) therapy to be greenlighted for solid tumors. Lifileucel is manufactured by collecting and expanding a patient's unique T cells from part of their tumor and then infusing them into that patient to fight the cancer. 

Oncotelic Therapeutics (OTCQB:OTLC) is looking to develop similar treatment therapies for ocular cancers, including retinoblastoma and uveal melanoma. The technology is named necroptosis therapies.

Oncotelic and Mosaic ImmunoEngineering, Inc. (OTC:CPMV) are developers of necroptosis therapies. The recent approval of TIL cell therapy demonstrates how to manipulate patient immunity against cancer for a lasting cure. However, TIL cell therapy is costly, time-consuming and technologically challenging. Instead of driving TIL cells externally, Necroptosis Cancer Therapies drive innate TILs to the tumor. The key step is the induction of necrotic cell death and activation of death genes, exposing tumor-reactive antigens to initiate an immune response, activating antigen-presenting ...

OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets>Full story available on Benzinga.com